Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 240
- Registration Number
- NCT02193776
- Locations
- 🇿🇦
Klerksdorp Tshepong Hospital, Jouberton, Klerksdorp, South Africa
🇿🇦The Aurum Institute: Tembisa Hospital, Tembisa, Gauteng, South Africa
🇹🇿NIMR-Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
- Conditions
- Multidrug Resistant Tuberculosis
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02120638
- Locations
- 🇨🇳
Chongqing Pulmonary Hospital, Chongqing, Chongqing, China
🇨🇳The Fifth People's Hospital of Wuxi, Wuxi, Jiangsu, China
🇨🇳The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China
Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- Dietary Supplement: pyridoxine
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 365
- Registration Number
- NCT01785186
- Locations
- 🇿🇦
The Aurum Institute for Health Research, Johannesburg, South Africa
🇿🇦University of Cape Town, Centre for Tuberculosis Research Innovation, Cape Town, South Africa
🇹🇿NIMR - Mbeya Medical Research Programme, Mbeya, Tanzania
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 105
- Registration Number
- NCT01691534
- Locations
- 🇿🇦
Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa
🇿🇦Task Applied Science, Karl Bremer Hospita, Cape Town, South Africa
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
- Conditions
- HIV InfectionTuberculosis
- Interventions
- Drug: Standard-dose Lopinavir/RitonavirDrug: Double-dose Lopinavir/Ritonavir
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 71
- Registration Number
- NCT01601626
- Locations
- 🇵🇪
Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇭🇹Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti
Essentiality of INH in TB Therapy
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 69
- Registration Number
- NCT01589497
- Locations
- 🇿🇦
TASK Applied Science CRS (31718), Bellville, South Africa
🇿🇦University of Cape Town Lung Institute (UCTLI) CRS (31792), Cape Town, Western Cape, South Africa
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 207
- Registration Number
- NCT01498419
- Locations
- 🇹🇿
Ifakara Health Institute, Bagamoyo, Tanzania
🇿🇦The Aurum Institute: Tembisa Hospital, Tembisa, South Africa
🇿🇦Klerksdorp Tshepong Hospital, Klerksdorp, South Africa
Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
- Conditions
- Tuberculosis, PulmonaryHepatitis
- Interventions
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2012-12-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01395654
- Locations
- 🇨🇳
Chest Hospital, Tainan, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 85
- Registration Number
- NCT01215851
- Locations
- 🇿🇦
Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa
🇿🇦Task Applied Science, Karl Bremer Hospital, Cape Town, South Africa
Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2019-12-09
- Target Recruit Count
- 19
- Registration Number
- NCT00816426
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of
🇰🇷National Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.